ADMA

ADMA Biologics, Inc. (ADMA) | Rumor.io

ADMA Biologics

ADMA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,241

Bullish sentiment (50-day avg)79%

Price to earnings ratio13.7

Market capitalization2.3B

Earnings per share0.7

Dividend yield (TTM)—

Revenue (annual)510.2M

Net income (annual)146.9M

Social

What share of all stock conversation is about ADMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Aug 6

ADMA Biologics reported Q2 earnings that met expectations, but the stock price remains low due to a short report and lack of growth.
The company's underlying business remains strong, with management doing what's expected, and the stock repurchase program continues to enhance shareholder value.
ADMA Biologics is projected to have mid-single-digit top-line growth in 2026, despite struggling with competition in one of its products, and some analysts see potential for a buyout or acquisition.

Generated by AI

Sentiment

Of the messages about ADMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	75% +44.23	45.45% -38.76	75.1% +29.28
Bearish	—	25% -44.23	54.55% +38.76	24.9% -29.28

Bullish· May 7

ADMA Biologics, Inc. has a strong potential for a short squeeze due to its 52-week low and company-initiated buyback.
The company's improved margins and solid growth in its lead product, ASCENIV, make it a strong candidate for future price appreciation.
With its strong cash flow, improving margins, and continued growth in ASCENIV, ADMA is well-positioned for a significant price increase in the near future.

Bearish· May 7

The company's share price has been impacted by a sharp selloff, but the structural picture hasn't changed, with a remaining buyback authorization of $340 million and a strong operating cash flow of $58 million.
The company's guidance for the year remains intact, with a revenue range of $530-560 million, but the recent Q1 softness was attributed to distributor ordering patterns and IG pricing pressure.
The shorting of the stock near its 52-week low during a buyback is a high-risk, contrarian strategy, as it could potentially lead to a short squeeze if the company aggressively buys shares to boost earnings per share (EPS).

Generated by AI

Topics

Of the messages about ADMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	9.73%
Technical Analysis	—	0%	0%	16.97%
Earnings	—	0%	0%	11.15%
Controversies	—	0%	0%	1.22%
Analysts	—	0%	0%	22.87%
Macro	—	0%	0%	38.06%

Earnings· Nov 5

ADMA Biologics, Inc. reported quarterly sales of $10.28 million, a 42.27% increase from the same period last year, beating the analyst consensus estimate of $9.96 million.
The company's third quarter revenue grew 42% year-over-year, with a strong quarter despite continued COVID-19 operating headwinds, and management expects to reach $250 million or more in revenue within the next three years.
ADMA Biologics, Inc. beat earnings per share (EPS) expectations, reporting a loss of $0.19, which was better than the consensus estimate of a loss of $0.21, and also beat revenue expectations.

Announcements· Apr 28

ADMA Biologics, Inc. announced U.S. FDA approval of its innovative yield enhancement production process, which increases production yields by approximately 20% from the same starting plasma volume.
The approval is expected to unlock meaningful acceleration in the company's revenue and earnings trajectory, starting in late 2025 and accelerating further into 2026 and beyond.
The company's innovative production yield enhancement process is the first U.S. regulatory approval of its kind, highlighting ADMA's uniquely efficient internal R&D engine and its leadership in modernizing and advancing plasma fractionation.

Technical Analysis· Sep 8

$ADMA is in a buy zone according to its money flow chart and is expected to experience a spike soon.
The company's volume chart has bottomed, indicating a likely spike in price.
$ADMA's price is expected to break out above $1.45, with some analysts predicting a double bottom at $1.24.

Generated by AI

Community

Of the messages about ADMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	14.71%	21.58%	35.39%	64.23%
Newcomers	85.29%	78.42%	64.61%	35.77%

Regulars· Aug 5

ADMA is expected to reach a three-digit valuation in the future, driven by the growth of ASCENIV and the company's expanding cash cow business, as well as a generous share buyback policy.
ADMA's share price is expected to return to the $20s in the short term, followed by $30-40, as ASCENIV continues to grow and the company executes its share buyback policy.
ADMA's Q2 earnings results show a 21.43% YoY increase in GAAP EPS and a 1.98% YoY increase in revenue, with the company reiterating its FY2026 financial guidance of $530 million to $560 million in total revenue.

Newcomers· Apr 29

Newcomers to ADMA Biologics, Inc. are focused on its recent FDA approval for a plasma yield enhancement process, which they believe can increase plasma-derived medication production by 20% and unlock significant growth for the company.
They are also discussing the stock's recent price movements, noting a 12.12% gain and a new all-time high, and attributing this to the FDA approval and the company's strong fundamentals.
Some newcomers are speculating that the stock may experience a surge in popularity among retail investors once they become aware of the approval, potentially leading to a significant increase in the stock's price.

Generated by AI

News

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.

15h agoYahoo! Finance Canada

ADMA Biologics (ADMA), Why Is It Back In The Spotlight?

Recent performance swings in ADMA Biologics (ADMA) have put fresh attention on what investors are paying for its plasma-derived therapies business after a year of sharp declines and a much stronger past 3 months. The recent rebound in ADMA Biologics, with a 12.07% 90‑day share price return, contrasts sharply with a year‑to‑date share price decline of 47.54%, while a very large 5‑year total shareholder return of about 7x signals that long‑term holders have seen substantial gains. Scan beyond...

2d agoYahoo Finance

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.

5d agoYahoo Finance

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

5d agoYahoo Finance

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

11d agoYahoo Finance

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

18d agoYahoo Finance

Also Discussed

Investors talking about ADMA also mention

#	Name	Attention
1	VBIV - VBI Vaccines Inc.	——
2	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
3	Kamada Ltd.KMDA	0%0
4	Planet Green Holdings Corp.PLAG	0%new
5	IDEAYA Biosciences Inc.IDYA	0%-0.01
6	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0.01
7	Precipio Inc.PRPO	0%0
8	ABIO - ARCA biopharma, Inc.	——
9	Karyopharm Therapeutics Inc.KPTI	0%new
10	DarioHealth Corp.DRIO	0%0

ADMA Biologics, Inc.

Healthcare
Biotechnology

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases. ADMA’s current portfolio includes FDA-approved immune globulin and hyperimmune products used to help treat primary humoral immunodeficiency, support immune-compromised patients, and provide protection in hepatitis B exposure settings. The company operates an integrated model that combines plasma collection, fractionation, purification, and commercialization, allowing it to support the supply of its therapies through its own manufacturing infrastructure. ADMA serves healthcare providers and patients in the United States and internationally, with a business centered on plasma-derived therapeutics and targeted immunology applications. Headquartered in Ramsey, New Jersey, ADMA Biologics plays a specialized role in the plasma medicines market by supplying niche biologic treatments for clinical use.

Website

Location

465 State Route 17

Ramsey, NJ, 07446

United States

Social

What share of all stock conversation is about ADMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.01

Aug 6

ADMA Biologics reported Q2 earnings that met expectations, but the stock price remains low due to a short report and lack of growth.
The company's underlying business remains strong, with management doing what's expected, and the stock repurchase program continues to enhance shareholder value.
ADMA Biologics is projected to have mid-single-digit top-line growth in 2026, despite struggling with competition in one of its products, and some analysts see potential for a buyout or acquisition.

Generated by AI

Sentiment

Of the messages about ADMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	75% +44.23	45.45% -38.76	75.1% +29.28
Bearish	—	25% -44.23	54.55% +38.76	24.9% -29.28

Bullish· May 7

ADMA Biologics, Inc. has a strong potential for a short squeeze due to its 52-week low and company-initiated buyback.
The company's improved margins and solid growth in its lead product, ASCENIV, make it a strong candidate for future price appreciation.
With its strong cash flow, improving margins, and continued growth in ASCENIV, ADMA is well-positioned for a significant price increase in the near future.

Bearish· May 7

The company's share price has been impacted by a sharp selloff, but the structural picture hasn't changed, with a remaining buyback authorization of $340 million and a strong operating cash flow of $58 million.
The company's guidance for the year remains intact, with a revenue range of $530-560 million, but the recent Q1 softness was attributed to distributor ordering patterns and IG pricing pressure.
The shorting of the stock near its 52-week low during a buyback is a high-risk, contrarian strategy, as it could potentially lead to a short squeeze if the company aggressively buys shares to boost earnings per share (EPS).

Generated by AI

Topics

Of the messages about ADMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	9.73%
Technical Analysis	—	0%	0%	16.97%
Earnings	—	0%	0%	11.15%
Controversies	—	0%	0%	1.22%
Analysts	—	0%	0%	22.87%
Macro	—	0%	0%	38.06%

Earnings· Nov 5

ADMA Biologics, Inc. reported quarterly sales of $10.28 million, a 42.27% increase from the same period last year, beating the analyst consensus estimate of $9.96 million.
The company's third quarter revenue grew 42% year-over-year, with a strong quarter despite continued COVID-19 operating headwinds, and management expects to reach $250 million or more in revenue within the next three years.
ADMA Biologics, Inc. beat earnings per share (EPS) expectations, reporting a loss of $0.19, which was better than the consensus estimate of a loss of $0.21, and also beat revenue expectations.

Announcements· Apr 28

ADMA Biologics, Inc. announced U.S. FDA approval of its innovative yield enhancement production process, which increases production yields by approximately 20% from the same starting plasma volume.
The approval is expected to unlock meaningful acceleration in the company's revenue and earnings trajectory, starting in late 2025 and accelerating further into 2026 and beyond.
The company's innovative production yield enhancement process is the first U.S. regulatory approval of its kind, highlighting ADMA's uniquely efficient internal R&D engine and its leadership in modernizing and advancing plasma fractionation.

Technical Analysis· Sep 8

$ADMA is in a buy zone according to its money flow chart and is expected to experience a spike soon.
The company's volume chart has bottomed, indicating a likely spike in price.
$ADMA's price is expected to break out above $1.45, with some analysts predicting a double bottom at $1.24.

Generated by AI

Community

Of the messages about ADMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	14.71%	21.58%	35.39%	64.23%
Newcomers	85.29%	78.42%	64.61%	35.77%

Regulars· Aug 5

ADMA is expected to reach a three-digit valuation in the future, driven by the growth of ASCENIV and the company's expanding cash cow business, as well as a generous share buyback policy.
ADMA's share price is expected to return to the $20s in the short term, followed by $30-40, as ASCENIV continues to grow and the company executes its share buyback policy.
ADMA's Q2 earnings results show a 21.43% YoY increase in GAAP EPS and a 1.98% YoY increase in revenue, with the company reiterating its FY2026 financial guidance of $530 million to $560 million in total revenue.

Newcomers· Apr 29

Newcomers to ADMA Biologics, Inc. are focused on its recent FDA approval for a plasma yield enhancement process, which they believe can increase plasma-derived medication production by 20% and unlock significant growth for the company.
They are also discussing the stock's recent price movements, noting a 12.12% gain and a new all-time high, and attributing this to the FDA approval and the company's strong fundamentals.
Some newcomers are speculating that the stock may experience a surge in popularity among retail investors once they become aware of the approval, potentially leading to a significant increase in the stock's price.

Generated by AI

ADMA Biologics

Social

Aug 6

Bullish· May 7

Bearish· May 7

Earnings· Nov 5

Announcements· Apr 28

Technical Analysis· Sep 8

Regulars· Aug 5

Newcomers· Apr 29

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

ADMA Biologics (ADMA), Why Is It Back In The Spotlight?

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Also Discussed

ADMA Biologics, Inc.

Company Information

Location

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

ADMA Biologics (ADMA), Why Is It Back In The Spotlight?

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Also Discussed

Social

Aug 6

Bullish· May 7

Bearish· May 7

Earnings· Nov 5

Announcements· Apr 28

Technical Analysis· Sep 8

Regulars· Aug 5

Newcomers· Apr 29